‘Small molecules are sexy again’: Gate Bioscience debuts with $60M and a new way to stop disease-causing proteins
01 Nov 2023
Gate Bioscience has raised $60 million to develop a new type of pill-based medicine — which it calls a molecular gate — that can go after the spectrum of malicious proteins.
The Brisbane, CA biotech was started in 2021 by Jordi Mata‐Fink, a member of the founding team for Generate:Biomedicines and now Gate’s CEO; Pat Sharp, whose postdoc work serves as the foundation for the company’s platform; and Raman Talwar, a former senior associate at Flagship Pioneering. The Series A round was led by Versant Ventures and Andreessen Horowitz (a16z), and investors also included ARCH Venture Partners and GV, Google’s venture arm.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
-Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.